Emcure Pharmaceuticals Ltd. has announced a significant reduction in the price of its weight management drug, Poviztra® (semaglutide injection), across India. The starting dose price has been slashed by 55%, making it available at ₹999 per week or ₹3,999 per month, inclusive of taxes. This move is aimed at expanding patient access to the drug.
The company has revised the prices of Poviztra® by an average of 47% across all doses. The drug, which is available in a once-weekly pen device, comes in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg. The revised pricing will take effect from April 3, 2026.
Emcure Pharmaceuticals is the first Indian company to exclusively distribute and commercialise Poviztra®, a second brand of Novo Nordisk’s semaglutide injection for obesity. The price revision is expected to make the innovator molecule, which is backed by robust clinical and real-world evidence, accessible to a significantly larger patient base in India.
The old and revised monthly prices for Poviztra® are as follows:
– Poviztra® 0.25 mg: ₹8,790 reduced to ₹3,999
– Poviztra® 0.5 mg: ₹11,200 reduced to ₹4,999
– Poviztra® 1 mg: ₹11,200 reduced to ₹5,999
– Poviztra® 1.7 mg: ₹13,000 reduced to ₹7,999
– Poviztra® 2.4 mg: ₹15,000 reduced to ₹8,999
Satish Mehta, CEO and Managing Director of Emcure Pharma, stated, “The revised pricing of Poviztra® is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base. India is grappling with a growing obesity epidemic, with nearly 254 million people living with generalised obesity and 351 million living with abdominal obesity. Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale.”
Obesity is linked to over 230 health complications, including cardiovascular disease, type 2 diabetes, hypertension, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease, and Alzheimer’s disease. With this price reduction, Emcure Pharma reinforces its commitment to advancing patient access, improving health outcomes, and supporting innovative treatments that address the growing burden of obesity in India.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).